Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method

Authors: Purvish Parikh, Govind Babu, Randeep Singh, Vamshi Krishna, Amit Bhatt, Indu Bansal, Senthil Rajappa, Tarini Prasad Sahoo, Shyam Aggarwal, Ajay Bapna, Ghanshyam Biswas, SP Somashekhar, Jyoti Bajpai, Vashishtha Maniar, Sharad Desai, T Raja, Goura Kishor Rath

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Precise prognostication is the key to optimum and effective treatment planning for early-stage hormone receptor (HR) positive, HER2/neu negative breast cancer patients. Differences in the breast cancer incidence and tumor anatomical features at diagnosis, pharmacogenomics data between Western and Indian women along with the vast diversity in the economic status and differences in insurance policies of these regions; suggest recommendations put forward for Western women might not be applicable to Indian/Asian women. Opinions from oncologists through a voting survey on various prognostic factors/tools to be considered for planning adjuvant therapy are consolidated in this report for the benefit of oncologists of the sub-continent, SAARC and Asia’s LMIC (low and middle-income countries).

Methods

A three-phase DELPHI survey was conducted to collect opinions on prognostic factors considered for planning adjuvant therapy in early-stage HR+/HER2/neu negative breast cancer patients. A panel of 25 oncologists with expertise in breast cancer participated in the survey conducted in 2021. The experts provided opinions as ‘agree’ or disagree’ or ‘not sure’ in phases-1 and 2 which were conducted virtually; in the final phase-3, all the panel experts met in person and concluded the survey.

Results

Opinions on 41 statements related to prognostic factors/tools and their implications in planning adjuvant endocrine/chemotherapy were collected. All the statements were supported by the latest data from the clinical trials (prospective/retrospective). The statements with opinions of consensus less than 66% were disseminated in phase-2, and later in phase-3 with supporting literature. In phase-3, all the opinions from panelists were consolidated and guidelines were framed.

Conclusions

This consensus guideline will assist oncologists of India, SAARC and LMIC countries in informed clinical decision-making on adjuvant treatment in early HR+/HER2/neu negative breast cancer patients.
Literature
1.
Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11:101–15.PubMedPubMedCentral
2.
Madhav MR, Nayagam SG, Biyani K, Pandey V, Kamal DG, Sabarimurugan S, et al. Epidemiologic analysis of breast cancer incidence, prevalence, and mortality in India: protocol for a systematic review and meta-analyses. Med (Baltim). 2018;97:e13680.CrossRef
3.
Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in indian women. Asia-Pac J Clin Oncol. 2017;13:289–95.PubMedCrossRef
4.
Chopra B, Kaur V, Singh K. Age shift: breast cancer is occurring in younger age groups: is it true? Clin. Cancer Investig J. 2014;3:526–9.CrossRef
5.
Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triple-negative breast cancer in India: systematic review and meta-analysis. J Glob oncol. 2016;2:412–21.PubMedPubMedCentralCrossRef
6.
Doval DC, Radhakrishna S, Tripathi R, et al. A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery. Sci Rep. 2020;10:5886.PubMedPubMedCentralCrossRef
7.
8.
Aggarwal S, Vaid A, Ramesh A, Parikh PM, Purohit S, Avasthi B, et al. Practical consensus recommendations on the management of HR + ve early breast cancer with specific reference to genomic profiling. South Asian J Cancer. 2018;7:96–101.PubMedPubMedCentralCrossRef
9.
Monticciolo DL, Helvie MA, Hendrick RE. Current issues in the overdiagnosis and overtreatment of breast Cancer. AJR Am J Roentgenol. 2018;210:285–91.PubMedCrossRef
10.
Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401–9.PubMedCrossRef
11.
Purvish MP, Hingmire Patil, Bhavesh KG, Prashant Mehta A, Verma SA, Bondarde, et al. Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care. Int J Mol ImmunoOncol. 2017;2:47–57.CrossRef
12.
Purvish M, Parikh​ P, Narayanan A, Vora A, Gulia SK, Mullapally B, Rangrajan, et al. Conflict of interest disclosure and interpretation - rest assured the medical professional in the audience is perceptive, alert and smart. Indian J Med Sci. 2019;71:4–8.CrossRef
13.
Purvish MP, Hingmire SS, Patil Bhavesh K, Govind P, Mehta A, Verma, et al. Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care. Int J Mol ImmunoOncol. 2017;2:47–57.CrossRef
14.
Purvish MP, Vora PNarayana, Gulia AG, Mullapally SK, Rangrajan B, et al. Conflict of interest disclosure and interpretation - rest assured the medical professional in the audience is perceptive, alert and smart. Indian J Med Sci. 2019;71:4–8.CrossRef
15.
Pelizzari G, Arpino G, Biganzoli L, et al. An italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. BMC Cancer. 2018;18:932.PubMedPubMedCentralCrossRef
16.
Puglisi F, Bisagni G, Ciccarese M, Fontanella C, Gamucci T, Leo L, et al. A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. Future Oncol. 2016;12:2589–602.PubMedCrossRef
17.
Mohile SG, Velarde C, Hurria A, Magnuson A, Lowenstein L, Pandya C, et al. Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts. J Natl Compr Cancer Netw. 2015;13:1120–30.CrossRef
18.
NCCN Breast. Cancer Treatment guidelines 2022.
19.
Soares GP, Pereira AAL, Vilas Boas MS, Vaisberg VV, Magalhães MCF, Linck RDM, Mano MS. Value of systemic staging in asymptomatic early breast Cancer. Rev Bras Ginecol Obstet. 2018;40:403–9.PubMedCrossRef
20.
Sarvari BK, Sankara Mahadev D, Rupa S, Mastan SA. Detection of bone metastases in breast Cancer (BC) patients by serum tartrate-resistant acid phosphatase 5b (TRACP 5b), a bone resorption marker and serum alkaline phosphatase (ALP), a bone formation marker, in Lieu of whole body skeletal scintigraphy with Technetium99m MDP. Indian J Clin Biochem. 2015;30:66–71.PubMedCrossRef
21.
White DR, Maloney JJ, Muss HB, et al. Serum alkaline phosphatase determination: value in the staging of advanced breast Cancer. JAMA. 1979;242:1147–9.PubMedCrossRef
22.
Chen WZ, Shen JF, Zhou Y, et al. Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. Sci Rep. 2017;7:11325.PubMedPubMedCentralCrossRef
23.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRef
24.
Pan H, Gray R, Jeremy Bray Brooke BM, et al. 20 years risks of breast-Cancer recurrence after stopping endocrine therapy at 5 years. N Eng J Med. 2017;377:1836–46.CrossRef
25.
Early breast cancer. Trialists’ collaborative group polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930e42.
26.
Bouchard-Fortier A, Provencher L, Blanchette C, Diorio C. Prognostic and predictive value of low estrogen receptor expression in breast cancer. Curr Oncol. 2017;24:e106–14.PubMedPubMedCentralCrossRef
27.
Kimberly HAM, Elizabeth HH, Dowsett M, Shannon EM, Lisa AC, Patrick LF, et al. Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38:1346–66.CrossRef
28.
Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast Cancer Working Group. J Natl Cancer Inst. 2020;113:808–19.PubMedCentralCrossRef
29.
Vieira A, Filipe S. Fernando. An Update on Breast Cancer Multigene Prognostic Tests—Emergent Clinical Biomarkers. Front. Med. 5, 2018, 1–2.
30.
31.
Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1.PubMedPubMedCentralCrossRef
32.
Cuzick J, Dowset M, Pinada S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4274–8.CrossRef
33.
Lambertini M, Pinto AC, Ameye L, et al. The prognostic performance of adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. Br J Cancer. 2016;115:1471–8.PubMedPubMedCentralCrossRef
34.
Wong HS, Subramaniam S, Alias Z, et al. The predictive accuracy of PREDICT: a personalized decision-making tool for southeast asian women with breast cancer. Med (Baltim). 2015;94:e593.CrossRef
35.
Maishman T, Copson E, Stanton L, Gerty S, Dicks E, Durcan L, et al. An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ≤ 40 years at breast cancer diagnosis. Br J Cancer. 2015;112:983e91.CrossRef
36.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast Cancer-major changes in the american Joint Committee on Cancer eighth edition cancer staging manual. Ca-Cancer J Clin. 2017;67:290–303.PubMedCrossRef
37.
Shi Jian L, Chen-Lu C, Feng Z, Ping L, Jian H, Li, et al. Prognostic and predictive value of the american Joint Committee on Cancer pathological prognostic staging system in nodal micrometastatic breast Cancer. Front Oncol. 2020;10:570175.PubMedPubMedCentralCrossRef
38.
RamKumar C, Buturovic L, Malpani S, et al. Development of a Novel Proteomic Risk-Classifier for Prognostication of patients with early-stage hormone receptor-positive breast Cancer. Biomark. Insights. 2018;13:1–9.
39.
Bakre MM, Ramkumar C, Attuluri AK, Basavaraj C, Prakash C, Buturovic L, et al. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor positive breast cancer patients. Cancer Med. 2019;8:1755–64.PubMedPubMedCentralCrossRef
40.
Doval DC, Mehta A, Somashekhar SP, et al. The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic indian origin. The Breast. 2021;59:1–7.CrossRef
41.
Gunda A, Basavaraj C, Chandra Prakash SV, Adinarayan M, Kolli R, Eshwaraiah MS, Saura C, et al. A retrospective validation of CanAssist breast in european early-stage breast cancer patient cohort. The Breast. 2022;63:1–8.PubMedPubMedCentralCrossRef
42.
Zhang X, Gunda A, Kranenbarg EM, Liefers GJ, Savitha BA, Shrivastava P, et al. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist breast (CAB) in dutch sub-cohort of the randomized TEAM trial. Breast Cancer Res. 2023;25:40.PubMedPubMedCentralCrossRef
43.
44.
Gong G, Kwon MJ, Han J, Lee HJ, Lee SK, Lee JE, et al. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer. Sci Rep. 2017;7:45554.PubMedPubMedCentralCrossRef
45.
Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, et al. Ethnicity, and clinical outcomes in hormone Receptor-Positive, HER2-Negative, node-negative breast Cancer in the Randomized TAILORx Trial. J Natl Cancer Inst. 2021;113:390–9.PubMedCrossRef
46.
47.
Lao C, Lawrenson R, Edwards M, Campbell I. Treatment and survival of asian women diagnosed with breast cancer in New Zealand. Breast Cancer Res Treat. 2019;177:497–505.PubMedCrossRef
48.
49.
Iqbal J, Ginsburg O, Rochon PA, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313:165–73.PubMedCrossRef
50.
Chen M, Kwong A, Hendricks C et al. Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients. Presented at 2020 San Antonio Breast Cancer Virtual Symposium December 8–11, 2020; San Antonio, Texas.
51.
Hoskins KF, Danciu OC, Ko NY, Calip GS. Association of Race/Ethnicity and the 21-Gene recurrence score with breast Cancer-specific mortality among US women. JAMA Oncol. 2021;7:370–8.PubMedCrossRef
52.
Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, et al. Clinical utility of the 70-gene MammaPrint profile in a japanese population. Jpn J Clin Oncol. 2010;40:508–12.PubMedCrossRef
53.
Sengupta AK, Gunda A, Malpani S, Serkad CPV, Basavaraj C, Bapat A, et al. Comparison of breast cancer prognostic tests CanAssist breast and oncotype DX. Cancer Med. 2020;9:7810–8.PubMedPubMedCentralCrossRef
54.
Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, et al. OPTIMA TMG. Comparing breast Cancer multiparameter tests in the OPTIMA Prelim Trial: no test is more equal than the others. J Natl Cancer Inst. 2016;108:djw050.PubMedPubMedCentralCrossRef
55.
Özmen V, Çakar B, Gökmen E, Özdoğan M, Güler N, Uras C, et al. Cost effectiveness of Gene expression profiling in patients with early-stage breast Cancer in a Middle-Income Country, Turkey: results of a prospective Multicenter Study. Eur J Breast Health. 2019;15:183–90.PubMedPubMedCentralCrossRef
56.
57.
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. NEJM. 2016;375:209–19.PubMedCrossRef
58.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Adjuvant tamoxifen: longer against shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.PubMedPubMedCentralCrossRef
59.
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant Tamoxifen-To offer more? (aTTom) trial. Ann Oncol. 2019;30:1776–83.PubMedPubMedCentralCrossRef
60.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206–23.PubMedPubMedCentralCrossRef
61.
Yoshio Mizuno H, Fuchikami N, Takeda J, Yamada Y, Inoue H, Seto. Kazuhiko Sato. Comparing oncotype DX Recurrence score categories with immunohistochemically defined Luminal subtypes. J of Cancer Ther. 2016;7:223–31.CrossRef
Metadata
Title
Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method
Authors
Purvish Parikh
Govind Babu
Randeep Singh
Vamshi Krishna
Amit Bhatt
Indu Bansal
Senthil Rajappa
Tarini Prasad Sahoo
Shyam Aggarwal
Ajay Bapna
Ghanshyam Biswas
SP Somashekhar
Jyoti Bajpai
Vashishtha Maniar
Sharad Desai
T Raja
Goura Kishor Rath
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11121-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma

Research

Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)

Research

Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis

Research

CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study

Research

Online decision tools for personalized survival prediction and treatment optimization in elderly patients with lung squamous cell carcinoma: a retrospective cohort study

Research

Assessing health-related quality of life among cancer survivors during systemic and radiation therapy in Bangladesh: a cancer-specific exploration

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits